Skip to main content
Premium Trial:

Request an Annual Quote

Rik van Heijningen

Premium
Rik van Heijningen has been named vice president of commercial operations for genomics and proteomics at Kreatech, the Dutch biotechnology company said last week.
 
According to Kreatech, van Heijningen will focus on corporate and business development for the firm’s protein, gene expression, and array comparative genomic hybridization reagent kits. 
 
Prior to joining Kreatech, van Heijningen held several sales and marketing positions with Dynal Biotech and Invitrogen in Norway, Germany, and The Netherlands.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.